Deterministic reprogramming and signaling activation following targeted therapy in non-small cell lung cancer driven by mutations or oncogenic fusions
R Rosell, C Pedraz-Valdunciel, A Jain… - Expert Opinion on …, 2024 - Taylor & Francis
Introduction Targeted therapy is used to treat lung adenocarcinoma caused by epidermal
growth factor receptor (EGFR) mutations in the tyrosine kinase domain and rare subtypes (< …
growth factor receptor (EGFR) mutations in the tyrosine kinase domain and rare subtypes (< …
Transcriptomic Profiling for Prognostic Biomarkers in Early-Stage Squamous Cell Lung Cancer (SqCLC)
Simple Summary Lung cancer is a leading cause of cancer-related deaths worldwide,
characterized as a disease usually diagnosed in the advanced stages with limited …
characterized as a disease usually diagnosed in the advanced stages with limited …
Concordance of ALK fusion gene-rearrangement between immunohistochemistry and next-generation sequencing
K Wakuda, M Morita, M Sekikawa, N Morikawa… - International Journal of …, 2024 - Springer
Background Although various companion diagnostic tests of ALK fusion gene-
rearrangement are approved, few reports have assessed the concordance of ALK fusion …
rearrangement are approved, few reports have assessed the concordance of ALK fusion …
[HTML][HTML] Shifting from Immunohistochemistry to Screen for ALK Rearrangements: Real-World Experience in a Large Single-Center Cohort of Patients with Non-Small …
M Ilié, S Goffinet, G Rignol, V Lespinet-Fabre, S Lalvée… - Cancers, 2024 - mdpi.com
Simple Summary Identifying ALK fusions in advanced non-small-cell lung carcinoma
(aNSCLC) is mandatory for targeted therapy. Current methods use ALK IHC, ALK FISH, or …
(aNSCLC) is mandatory for targeted therapy. Current methods use ALK IHC, ALK FISH, or …
[HTML][HTML] TIMM17A overexpression in lung adenocarcinoma and its association with prognosis
L Miao, D Wu, H Zhao, A Xie - Scientific Reports, 2024 - nature.com
Lung adenocarcinoma (LUAD), a leading cause of cancer-related mortality worldwide,
demands a deeper understanding of its molecular mechanisms and the identification of …
demands a deeper understanding of its molecular mechanisms and the identification of …
Benefits of NGS in Advanced Lung Adenocarcinoma Vary by Populations and Timing of Examination
PH Lee, WF Ou, YH Huang, KH Hsu, JS Tseng… - International Journal of …, 2024 - mdpi.com
Despite the widespread application of next-generation sequencing (NGS) in advanced lung
adenocarcinoma, its impact on survival and the optimal timing for the examination remain …
adenocarcinoma, its impact on survival and the optimal timing for the examination remain …
Platinum-based targeted chemotherapies and reversal of cisplatin resistance in non-small cell lung cancer (NSCLC)
Lung cancer is the one of the most prevalent cancer in the world. It kills more people from
cancer than any other cause and is especially common in underdeveloped nations. With 1.2 …
cancer than any other cause and is especially common in underdeveloped nations. With 1.2 …
A novel framework to assess haematology and oncology registration trials: The THEOREMM project
Background Methodological limitations affect a significant number of oncology and
haematology trials, raising concerns about the applicability of their results. For example, a …
haematology trials, raising concerns about the applicability of their results. For example, a …
Treatment sequencing after failure to alectinib in patients with anaplastic lymphoma kinase‐positive non‐small‐cell lung cancer
Y Shimomura, K Sawa, T Imai, Y Ihara… - Cancer …, 2024 - Wiley Online Library
Alectinib is the first‐line therapy for anaplastic lymphoma kinase‐positive non‐small‐cell
lung cancer. Although some guidelines have recommended using other anaplastic …
lung cancer. Although some guidelines have recommended using other anaplastic …
[HTML][HTML] A novel subtype based on driver methylation–transcription in lung adenocarcinoma
X Wang, Z Xu, S Zhao, J Song, Y Yu, H Yang… - Journal of Cancer …, 2024 - Springer
Aims To identify driver methylation genes and a novel subtype of lung adenocarcinoma
(LUAD) by multi-omics and elucidate its molecular features and clinical significance …
(LUAD) by multi-omics and elucidate its molecular features and clinical significance …